The Food and Drug Administration Office of Women's Health: impact of science on regulatory policy.
In 1994, the Food and Drug Administration Office of Women's Health (FDA-OWH) was created to provide leadership and policy direction for the Agency regarding issues of women's health. Within its first year, the FDA-OWH established a science program for women's health research, promoting the development of sound policy and regulation. In a little over a decade, the program has provided approximately 14 million dollars to fund more than 100 women's health research studies covering a broad range of health topics affecting women across their lifespan. Some studies, such as those elucidating drug effects on QT prolongation in women and drug-dietary supplement interaction, have had significant influence on regulatory decisions. Other studies have provided sound scientific data on sex and gender differences supporting FDA guidelines to protect women's health. This paper describes the science program at the FDA-OWH, providing examples of how funded research impacts regulatory policy.
Obias-Manno
Dulce
D
Food and Drug Administration, FDA/OC/Office of Women's Health, Rockville, Maryland 20857, USA.
Scott
Pamela E
PE
Kaczmarczyk
Joseph
J
Miller
Margaret
M
Pinnow
Ellen
E
Lee-Bishop
Lynda
L
Jones-London
Michelle
M
Chapman
Kennerly
K
Kallgren
Deborah
D
Uhl
Kathleen
K
D016907:Adverse Drug Reaction Reporting Systems / Q000331:legislation & jurisprudence; D002017:Budgets; D005260:Female; D006291:Health Policy / Q000191:economics / Q000331:legislation & jurisprudence* / Q000639:trends; D006801:Humans; D007857:Leadership; D011050:Policy Making; D012106:Research / Q000191:economics / Q000331:legislation & jurisprudence*; D014481:United States; D014486:United States Food and Drug Administration / Q000191:economics* / Q000458:organization & administration; D016387:Women's Health